Development
NeuroOne Medical Technologies Corporation
NMTC
$0.5817
-$0.0073-1.24%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 31.79% | 17.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 31.79% | 17.76% | |||
| Cost of Revenue | -5.71% | 2.18% | |||
| Gross Profit | 23.25% | 3.77% | |||
| SG&A Expenses | 37.65% | -15.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.82% | -5.64% | |||
| Operating Income | -7.13% | 9.84% | |||
| Income Before Tax | -6.69% | 9.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.69% | 9.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.69% | 9.62% | |||
| EBIT | -7.13% | 9.84% | |||
| EBITDA | -7.40% | 10.17% | |||
| EPS Basic | 0.99% | 28.64% | |||
| Normalized Basic EPS | 3.97% | 26.44% | |||
| EPS Diluted | 0.99% | 28.64% | |||
| Normalized Diluted EPS | 3.97% | 26.44% | |||
| Average Basic Shares Outstanding | 7.78% | 26.65% | |||
| Average Diluted Shares Outstanding | 7.78% | 26.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||